




RealRate

PHARMACEUTICAL 2021

ENDONOVO THERAPEUTICS INC.
Rank 236 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2021

ENDONOVO THERAPEUTICS INC. Rank 236 of 409

The relative strengths and weaknesses of ENDONOVO THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDONOVO THERAPEUTICS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 155% points. The greatest weakness of ENDONOVO THERAPEUTICS INC. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -178%, being 177% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	46
Cost of Goods Sold	65
Intangible Assets	2,559
Liabilities, Current	16,826
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	3,013
Other Liabilities	155
Other Net Income	2,517
Property and Equipment	1.6
Research and Development	0
Revenues	166
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	2,607
Liabilities	16,981
Expenses	3,078
Stockholders Equity	-14,374
Net Income	-396
Comprehensive Net Income	-396
Economic Capital Ratio	-178%

